
    
      This is a non-randomize, open label, Pilot phase II study with 5 consenting subjects. The
      specific aims of this study are:

      Aim 1: Quantitate local tumor response in patients with incurable AHNC treated with I-PDT
      with Temoporfin.

      Aim 2: Evaluate the changes in QoL in patients with incurable AHNC treated with I-PDT with
      Temoporfin.
    
  